Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →GEN detailed the deal terms: $75M upfront, up to $665M in milestones, double-digit royalties, plus a US/Canada co-promote and profit-sharing option — Janssen's…
MacroGenics confirmed deal closing on June 28, 2016, triggering the $75M upfront — validating company narrative that DART platform partnering remained a viable…
BioPharma Dive (covering the related MGD011 termination): the decision 'raises questions about the promise of MacroGenics' DART platform' as competitive…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
MacroGenics granted Janssen a global, exclusive license to MGD015, a preclinical CD3 x tumor-target bispecific DART molecule. MacroGenics received $75M upfront plus up to $665M in clinical, regulatory, and commercialization milestones (~$740M total) plus tiered royalties on global sales. Second deal between the parties (followed 2014 MGD011 deal).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Janssen Biotech, Inc. (Johnson & Johnson) / MacroGenics, Inc. (this deal) | 2016 | $740M | — |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals | 2013 | $886M | 79 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
← Browse all deals · How we score deals
More: 2016 deals · Hematology deals